查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070381

慢性疼痛治療​​市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026-2034年預測。

Chronic Pain Drugs Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

慢性疼痛治療​​市場的成長要素

由於長期疼痛疾病盛行率不斷上升、人口老化以及對更安全疼痛管理療法的需求日益成長，全球慢性疼痛治療​​市場正經歷穩定成長。慢性疼痛影響全球數百萬患者，包括肌肉骨骼疾病、神經病變疼痛、癌症相關疼痛、偏頭痛和術後疼痛患者。製藥公司正積極投資於創新非鴉片類藥物療法和標靶治療方法，以滿足患者尚未被滿足的需求。

市場規模與市場價值

2025年全球慢性疼痛治療​​市場價值為525億美元，預計2026年將達546億美元。此外，在慢性疼痛盛行率不斷上升和疼痛管理療法不斷進步的推動下，預計到2034年，該市場將成長至748億美元。

年度市場規模（十億美元）

2025 52.50

2026 54.60

2034 74.80

到 2025 年，北美將引領全球市場，佔總收入的 34.0%，這得益於高診斷率、先進的醫療保健基礎設施以及對創新止痛藥的積極採用。

主要市場趨勢

慢性疼痛治療​​市場最重要的趨勢之一是轉向非鴉片類鎮痛療法的轉變。人們對鴉片類藥物成癮、濫用和長期安全風險的擔憂，促使醫療專業人員和製藥公司將重點放在更安全的替代療法上。

2025年1月，Vertex Pharmaceuticals公司的JOURNAVX（舒吉三嗪）獲得FDA批准，這是一種用於治療中度至重度急性疼痛的非鴉片類藥物。此舉凸顯了業界正朝著標靶、非成癮性疼痛管理方案的方向轉變。

市場促進因素

人口老化促使對疼痛管理的需求增加

人口老化加劇是慢性疼痛藥物市場的主要成長要素。老年人更容易患骨關節炎、背痛、神經病變和其他需要長期治療的慢性疾病。

根據世界衛生組織2025年發布的估計數據，全球60歲及以上人口預計將從2023年的11億增加到2030年的14億。老年人慢性疼痛負擔的日益惡化持續推動著市場擴張。

市場限制因素

關於鴉片類藥物使用的監管問題

長期使用鴉片類藥物仍有成癮、過量和依賴的風險。監管機構正在實施更嚴格的處方指南，限制鴉片類藥物療法的成長潛力。

2025 年 7 月，美國食品藥物管理局(FDA) 在審查了有關濫用、鴉片類藥物使用障礙和過量用藥風險的證據後，加強了對鴉片類止痛藥的安全警告。

市場機遇

個別化與針對特異性的治療

醫療專業人員正日益採用針對特定疾病的個人化疼痛管理方法。這一趨勢為神經病變疼痛、骨關節炎和術後疼痛的標靶治療創造了機會。

2025 年 5 月，TRemedical 啟動了 TRD205 治療慢性術後神經病變疼痛的 II 期臨床試驗，這表明人們對特異性適應症的治療方案越來越感興趣。

市場挑戰

與非類固醇抗發炎藥相關的長期安全問題

雖然非類固醇抗發炎藥物（NSAIDs）仍廣泛用於慢性疼痛管理，但長期使用可能會增加心血管併發症的風險，包括心肌梗塞和中風。這些擔憂正推動著更安全的替代療法的研發。

區域分析

北美洲

預計到 2025 年，北美市場規模將達到 178.5 億美元，憑藉其先進的醫療保健系統、龐大的患者群體以及對創新療法的積極採用，將保持領先地位。

歐洲

在歐洲，受人口老化和慢性疼痛疾病盛行率上升等因素的推動，經濟持續穩定成長。

亞太地區

由於人口快速老化、醫療保健服務不斷改善以及人們對慢性疼痛管理的認知不斷提高，亞太地區正在成為重要的成長區域。

拉丁美洲、中東和非洲

預計這些地區將經歷適度成長，這得益於醫療基礎設施的改善和診斷率的提高。

2025年5月，禮來公司收購了SiteOne Therapeutics，以加強其非鴉片類鎮痛療法的產品線。這顯示該產業正致力於研發下一代鎮痛療法。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要地區主要疾病的流行情況
  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）
  • 主要國家和地區的監管趨勢
  • 2025年各地區主要創業公司

第5章：2021-2034年全球慢性疼痛治療​​市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • NSAIDs
    • 鴉片類藥物
    • 抗憂鬱症
    • 抗驚厥藥/加巴噴丁類藥物
    • 局部止痛藥
    • 局部麻醉劑
    • 大麻素藥物
    • 其他
  • 市場分析、洞察與預測：按疾病適應症分類
    • 肌肉骨骼疼痛
    • 神經病變疼痛
    • 癌症相關疼痛
    • 術後/創傷後疼痛
    • 內臟疼痛
    • 頭痛/口腔臉部疼痛
    • 原發性疼痛症候群
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按類型
    • 品牌
    • 非專利的
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 專科藥房
    • 藥局和零售藥房
    • 網路藥房
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美慢性疼痛治療​​市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲慢性疼痛治療​​市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區慢性疼痛治療​​市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲慢性疼痛治療​​市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東和非洲慢性疼痛治療​​市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Viatris Inc.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Amgen Inc.
    • H. Lundbeck A/S
    • Grunenthal GmbH
    • Collegium Pharmaceutical, Inc.
    • Haleon plc
    • Kenvue Inc.
Product Code: FBI115944

Growth Factors of chronic pain drugs Market

The global chronic pain drugs market is witnessing steady growth due to the increasing prevalence of long-term pain conditions, rising geriatric population, and growing demand for safer pain management therapies. Chronic pain affects millions of patients worldwide suffering from musculoskeletal disorders, neuropathic pain, cancer-related pain, migraine, and post-surgical pain. Pharmaceutical companies are actively investing in innovative non-opioid therapies and targeted treatment approaches to address unmet patient needs.

Market Size and Market Value

The global chronic pain drugs market was valued at USD 52.50 billion in 2025 and is projected to reach USD 54.60 billion in 2026. The market is further expected to grow to USD 74.80 billion by 2034, driven by increasing chronic pain prevalence and continuous advancements in pain management therapies.

Year Market Value (USD Billion)

2025 52.50

2026 54.60

2034 74.80

North America dominated the global market in 2025, accounting for 34.0% of total revenue due to high diagnosis rates, advanced healthcare infrastructure, and strong adoption of innovative pain medications.

Key Market Trends

One of the most significant trends shaping the chronic pain drugs market is the growing shift toward non-opioid pain management therapies. Concerns regarding opioid addiction, misuse, and long-term safety risks have encouraged healthcare providers and pharmaceutical companies to focus on safer alternatives.

In January 2025, Vertex Pharmaceuticals received FDA approval for JOURNAVX (suzetrigine), a non-opioid treatment for moderate-to-severe acute pain. Such developments highlight the industry's transition toward targeted and addiction-free pain management solutions.

Market Drivers

Growing Aging Population Increasing Demand for Pain Management

The expanding elderly population is a major growth driver for the chronic pain drugs market. Older adults are more vulnerable to osteoarthritis, lower back pain, neuropathic disorders, and other chronic conditions requiring long-term treatment.

According to WHO estimates published in 2025, the global population aged 60 years and above is expected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. The increasing burden of chronic pain among aging individuals continues to support market expansion.

Market Restraints

Regulatory Concerns Regarding Opioid Usage

Long-term opioid use remains associated with addiction, overdose, and dependency risks. Regulatory agencies are implementing stricter prescribing guidelines, limiting the growth potential of opioid-based therapies.

In July 2025, the U.S. FDA strengthened safety warnings for opioid pain medications after reviewing evidence related to misuse, opioid use disorder, and overdose risks.

Market Opportunities

Personalized and Indication-Specific Therapies

Healthcare providers are increasingly adopting personalized pain management approaches tailored to specific disease conditions. This trend is creating opportunities for targeted therapies designed for neuropathic pain, osteoarthritis, and post-surgical pain.

In May 2025, TRemedical initiated a Phase II trial of TRD205 for chronic post-surgical neuropathic pain, demonstrating growing interest in indication-specific treatment solutions.

Market Challenges

Long-Term Safety Concerns Associated with NSAIDs

Although NSAIDs remain widely used in chronic pain management, long-term usage may increase the risk of cardiovascular complications, including heart attack and stroke. These concerns encourage the development of safer alternative therapies.

Segment Analysis

By Drug Class

The NSAIDs segment dominated the market in 2025 due to widespread use in osteoarthritis, joint pain, and musculoskeletal disorders. Their affordability and broad clinical utility continue to drive demand.

The cannabinoid-based drugs segment is expected to witness the fastest growth due to increasing research and acceptance of alternative pain therapies.

By Disease Indication

The musculoskeletal pain segment held the largest market share in 2025. Conditions such as osteoarthritis, chronic back pain, and neck pain continue to generate significant demand for pain management medications.

By Age Group

The adult segment accounted for the largest share owing to the high prevalence of chronic pain among working-age and elderly populations.

By Product Type

Generic drugs dominated the market because they offer cost-effective treatment options for long-term therapy.

By Route of Administration

The oral segment led the market due to convenience, ease of administration, and suitability for long-term outpatient treatment.

By Distribution Channel

Drug stores and retail pharmacies remained the leading distribution channel owing to easy patient access and strong prescription refill volumes.

Regional Analysis

North America

North America generated USD 17.85 billion in 2025, maintaining its leadership position due to advanced healthcare systems, large patient populations, and strong adoption of innovative therapies.

Europe

Europe continues to experience steady growth driven by an aging population and increasing prevalence of chronic pain disorders.

Asia Pacific

Asia Pacific is emerging as a significant growth region due to rapid population aging, improving healthcare access, and increasing awareness of chronic pain management.

Latin America and Middle East & Africa

These regions are expected to witness moderate growth supported by healthcare infrastructure development and growing diagnosis rates.

Competitive Landscape

The market remains fragmented, with major players focusing on acquisitions, product launches, strategic partnerships, and research investments.

Key companies operating in the market include:

  • Viatris Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Lundbeck A/S
  • Grunenthal GmbH

In May 2025, Eli Lilly acquired SiteOne Therapeutics to strengthen its non-opioid pain treatment pipeline, highlighting the industry's focus on next-generation pain therapies.

Conclusion

The chronic pain drugs market is expected to witness sustained growth between 2025 and 2034, supported by rising chronic pain prevalence, an expanding geriatric population, and increasing demand for safer non-opioid treatment options. While regulatory scrutiny around opioids and safety concerns related to NSAIDs remain challenges, ongoing innovation in personalized medicine, targeted therapies, and non-addictive pain management solutions is creating significant growth opportunities. With market value projected to increase from USD 52.50 billion in 2025 to USD 74.80 billion by 2034, the industry is poised for continued expansion as pharmaceutical companies invest heavily in advanced chronic pain treatment technologies.

Segmentation By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region

By Drug Class * NSAIDs

  • Opioids
  • Antidepressants
  • Anticonvulsants / Gabapentinoids
  • Topical Analgesics
  • Local Anesthetics
  • Cannabinoid-based Drugs
  • NMDA Receptor Antagonists

By Disease Indication * Musculoskeletal Pain

  • Neuropathic Pain
  • Cancer-related Pain
  • Postsurgical / Post-traumatic Pain
  • Visceral Pain
  • Headache / Orofacial Pain
  • Primary Pain Syndromes
  • Others

By Age Group * Pediatric

  • Adults

By Type * Branded

  • Generic

By Route of Administration * Oral

  • Parenteral

By Distribution Channel * Hospital Pharmacies

  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
  • Others

By Region * North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Region
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.4. Regulatory Scenario, By Key Countries/Regions
  • 4.5. Key Start Up, By Key Regions, 2025

5. Global Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. NSAIDs
    • 5.1.2. Opioids
    • 5.1.3. Antidepressants
    • 5.1.4. Anticonvulsants / Gabapentinoids
    • 5.1.5. Topical Analgesics
    • 5.1.6. Local Anesthetics
    • 5.1.7. Cannabinoid-based Drugs
    • 5.1.8. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Musculoskeletal Pain
    • 5.2.2. Neuropathic Pain
    • 5.2.3. Cancer-related Pain
    • 5.2.4. Postsurgical / Post-traumatic Pain
    • 5.2.5. Visceral Pain
    • 5.2.6. Headache / Orofacial Pain
    • 5.2.7. Primary Pain Syndromes
    • 5.2.8. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adult
  • 5.4. Market Analysis, Insights and Forecast - By Type
    • 5.4.1. Branded
    • 5.4.2. Generic
  • 5.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.5.1. Oral
    • 5.5.2. Parenteral
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Speciality Pharmacies
    • 5.6.3. Drug Stores & Retail Pharmacies
    • 5.6.4. Online Pharmacies
    • 5.6.5. Others
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. NSAIDs
    • 6.1.2. Opioids
    • 6.1.3. Antidepressants
    • 6.1.4. Anticonvulsants / Gabapentinoids
    • 6.1.5. Topical Analgesics
    • 6.1.6. Local Anesthetics
    • 6.1.7. Cannabinoid-based Drugs
    • 6.1.8. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Musculoskeletal Pain
    • 6.2.2. Neuropathic Pain
    • 6.2.3. Cancer-related Pain
    • 6.2.4. Postsurgical / Post-traumatic Pain
    • 6.2.5. Visceral Pain
    • 6.2.6. Headache / Orofacial Pain
    • 6.2.7. Primary Pain Syndromes
    • 6.2.8. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adult
  • 6.4. Market Analysis, Insights and Forecast - By Type
    • 6.4.1. Branded
    • 6.4.2. Generic
  • 6.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.5.1. Oral
    • 6.5.2. Parenteral
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Drug Stores & Retail Pharmacies
    • 6.6.3. Speciality Pharmacies
    • 6.6.4. Online Pharmacies
    • 6.6.5. Others
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. NSAIDs
    • 7.1.2. Opioids
    • 7.1.3. Antidepressants
    • 7.1.4. Anticonvulsants / Gabapentinoids
    • 7.1.5. Topical Analgesics
    • 7.1.6. Local Anesthetics
    • 7.1.7. Cannabinoid-based Drugs
    • 7.1.8. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Musculoskeletal Pain
    • 7.2.2. Neuropathic Pain
    • 7.2.3. Cancer-related Pain
    • 7.2.4. Postsurgical / Post-traumatic Pain
    • 7.2.5. Visceral Pain
    • 7.2.6. Headache / Orofacial Pain
    • 7.2.7. Primary Pain Syndromes
    • 7.2.8. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adult
  • 7.4. Market Analysis, Insights and Forecast - By Type
    • 7.4.1. Branded
    • 7.4.2. Generic
  • 7.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.5.1. Oral
    • 7.5.2. Parenteral
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Drug Stores & Retail Pharmacies
    • 7.6.3. Speciality Pharmacies
    • 7.6.4. Online Pharmacies
    • 7.6.5. Others
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. NSAIDs
    • 8.1.2. Opioids
    • 8.1.3. Antidepressants
    • 8.1.4. Anticonvulsants / Gabapentinoids
    • 8.1.5. Topical Analgesics
    • 8.1.6. Local Anesthetics
    • 8.1.7. Cannabinoid-based Drugs
    • 8.1.8. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Musculoskeletal Pain
    • 8.2.2. Neuropathic Pain
    • 8.2.3. Cancer-related Pain
    • 8.2.4. Postsurgical / Post-traumatic Pain
    • 8.2.5. Visceral Pain
    • 8.2.6. Headache / Orofacial Pain
    • 8.2.7. Primary Pain Syndromes
    • 8.2.8. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adult
  • 8.4. Market Analysis, Insights and Forecast - By Type
    • 8.4.1. Branded
    • 8.4.2. Generic
  • 8.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.5.1. Oral
    • 8.5.2. Parenteral
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Drug Stores & Retail Pharmacies
    • 8.6.3. Speciality Pharmacies
    • 8.6.4. Online Pharmacies
    • 8.6.5. Others
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Southeast Asia
    • 8.7.5. Australia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. NSAIDs
    • 9.1.2. Opioids
    • 9.1.3. Antidepressants
    • 9.1.4. Anticonvulsants / Gabapentinoids
    • 9.1.5. Topical Analgesics
    • 9.1.6. Local Anesthetics
    • 9.1.7. Cannabinoid-based Drugs
    • 9.1.8. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Musculoskeletal Pain
    • 9.2.2. Neuropathic Pain
    • 9.2.3. Cancer-related Pain
    • 9.2.4. Postsurgical / Post-traumatic Pain
    • 9.2.5. Visceral Pain
    • 9.2.6. Headache / Orofacial Pain
    • 9.2.7. Primary Pain Syndromes
    • 9.2.8. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adult
  • 9.4. Market Analysis, Insights and Forecast - By Type
    • 9.4.1. Branded
    • 9.4.2. Generic
  • 9.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.5.1. Oral
    • 9.5.2. Parenteral
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Drug Stores & Retail Pharmacies
    • 9.6.3. Speciality Pharmacies
    • 9.6.4. Online Pharmacies
    • 9.6.5. Others
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. NSAIDs
    • 10.1.2. Opioids
    • 10.1.3. Antidepressants
    • 10.1.4. Anticonvulsants / Gabapentinoids
    • 10.1.5. Topical Analgesics
    • 10.1.6. Local Anesthetics
    • 10.1.7. Cannabinoid-based Drugs
    • 10.1.8. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Musculoskeletal Pain
    • 10.2.2. Neuropathic Pain
    • 10.2.3. Cancer-related Pain
    • 10.2.4. Postsurgical / Post-traumatic Pain
    • 10.2.5. Visceral Pain
    • 10.2.6. Headache / Orofacial Pain
    • 10.2.7. Primary Pain Syndromes
    • 10.2.8. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adult
  • 10.4. Market Analysis, Insights and Forecast - By Type
    • 10.4.1. Branded
    • 10.4.2. Generic
  • 10.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.5.1. Oral
    • 10.5.2. Parenteral
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Drug Stores & Retail Pharmacies
    • 10.6.3. Speciality Pharmacies
    • 10.6.4. Online Pharmacies
    • 10.6.5. Others
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Viatris Inc.
    • 11.2.2. Eli Lilly and Company
    • 11.2.3. AbbVie Inc.
    • 11.2.4. Teva Pharmaceutical Industries Ltd.
    • 11.2.5. Amgen Inc.
    • 11.2.6. H. Lundbeck A/S
    • 11.2.7. Grunenthal GmbH
    • 11.2.8. Collegium Pharmaceutical, Inc.
    • 11.2.9. Haleon plc
    • 11.2.10. Kenvue Inc.

List of Tables

  • Figure 1: Global Chronic Pain Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Chronic Pain Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Chronic Pain Drugs Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 5: Global Chronic Pain Drugs Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 6: Global Chronic Pain Drugs Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Chronic Pain Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Chronic Pain Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 8: Global Chronic Pain Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America Chronic Pain Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 10: North America Chronic Pain Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 11: North America Chronic Pain Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Chronic Pain Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 15: North America Chronic Pain Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 16: North America Chronic Pain Drugs Market Value Share (%), by Age Group, 2025
  • Figure 17: North America Chronic Pain Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: North America Chronic Pain Drugs Market Value Share (%), by Type, 2025
  • Figure 13: North America Chronic Pain Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 14: North America Chronic Pain Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 19: North America Chronic Pain Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Chronic Pain Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Chronic Pain Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 22: North America Chronic Pain Drugs Market Value Share (%), by Country, 2025
  • Figure 23: Europe Chronic Pain Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 24: Europe Chronic Pain Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 25: Europe Chronic Pain Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 26: Europe Chronic Pain Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 29: Europe Chronic Pain Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 30: Europe Chronic Pain Drugs Market Value Share (%), by Age Group, 2025
  • Figure 31: Europe Chronic Pain Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 32: Europe Chronic Pain Drugs Market Value Share (%), by Type, 2025
  • Figure 27: Europe Chronic Pain Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 28: Europe Chronic Pain Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 33: Europe Chronic Pain Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Europe Chronic Pain Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Chronic Pain Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Chronic Pain Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Chronic Pain Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Asia Pacific Chronic Pain Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 39: Asia Pacific Chronic Pain Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 40: Asia Pacific Chronic Pain Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Asia Pacific Chronic Pain Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 44: Asia Pacific Chronic Pain Drugs Market Value Share (%), by Age Group, 2025
  • Figure 45: Asia Pacific Chronic Pain Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 46: Asia Pacific Chronic Pain Drugs Market Value Share (%), by Type, 2025
  • Figure 41: Asia Pacific Chronic Pain Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 42: Asia Pacific Chronic Pain Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 47: Asia Pacific Chronic Pain Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 48: Asia Pacific Chronic Pain Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 49: Asia Pacific Chronic Pain Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Chronic Pain Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Chronic Pain Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 52: Latin America Chronic Pain Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 53: Latin America Chronic Pain Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 54: Latin America Chronic Pain Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 57: Latin America Chronic Pain Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 58: Latin America Chronic Pain Drugs Market Value Share (%), by Age Group, 2025
  • Figure 59: Latin America Chronic Pain Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 60: Latin America Chronic Pain Drugs Market Value Share (%), by Type, 2025
  • Figure 55: Latin America Chronic Pain Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 56: Latin America Chronic Pain Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 61: Latin America Chronic Pain Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 62: Latin America Chronic Pain Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 63: Latin America Chronic Pain Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Chronic Pain Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Chronic Pain Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 66: Middle East & Africa Chronic Pain Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 67: Middle East & Africa Chronic Pain Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 68: Middle East & Africa Chronic Pain Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 71: Middle East & Africa Chronic Pain Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 72: Middle East & Africa Chronic Pain Drugs Market Value Share (%), by Age Group, 2025
  • Figure 73: Middle East & Africa Chronic Pain Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 74: Middle East & Africa Chronic Pain Drugs Market Value Share (%), by Type, 2025
  • Figure 69: Middle East & Africa Chronic Pain Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 70: Middle East & Africa Chronic Pain Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 75: Middle East & Africa Chronic Pain Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 76: Middle East & Africa Chronic Pain Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 77: Middle East & Africa Chronic Pain Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Chronic Pain Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Chronic Pain Drugs Market Share (%), by Company, 2025